Dr. Korde is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1275 York Ave
New York, NY 10065Phone+1 212-639-7664- Is this information wrong?
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Temple University HospitalResidency, Internal Medicine, 2005 - 2008
Rutgers Robert Wood Johnson Medical SchoolClass of 2005
Certifications & Licensure
FL State Medical License 2022 - Present
NJ State Medical License 2016 - 2025
NY State Medical License 2008 - 2025
NC State Medical License 2020 - 2022
PA State Medical License 2005 - 2008- American Board of Internal Medicine Hematology
Clinical Trials
- High Dose Carfilzomib for Newly Diagnosed Myeloma Start of enrollment: 2016 Oct 01
- Mobile Health Device Study for Myeloma Patients Start of enrollment: 2016 Dec 01
Publications & Presentations
PubMed
- Unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies.Anna J Howard, Isabel Concepcion, Alice X Wang, Issam S Hamadeh, Malin L Hultcrantz, Sham Mailankody, Carlyn Rose Tan, Neha Korde, Alexander M Lesokhin, Hani Hassoun, ...> ;Blood Advances. 2024 Apr 12
- Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy.Issam S Hamadeh, Tala Shekarkhand, Colin Joseph Rueda, Ross S Firestone, Alice X Wang, Neha Korde, Malin L Hultcrantz, Alexander M Lesokhin, Sham Mailankody, Hani Hass...> ;Blood Advances. 2024 Apr 10
- 1 citationsCD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.Ross S Firestone, Devin McAvoy, Tala Shekarkhand, Edith Serrano, Issam Hamadeh, Alice Wang, Menglei Zhu, Wei Ge Qin, Dhwani Patel, Carlyn R Tan, Malin Hultcrantz, Sham...> ;Blood Advances. 2024 Apr 9
- Join now to see all
Abstracts/Posters
- Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...Neha Korde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients ...Neha Korde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban ProphylaxisNeha Korde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term D...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Multiple Myeloma Research Foundation (MMRF) and Memorial Sloan Kettering (MSK) Cancer Center Collaborate on Minimal Residual Disease (MRD) Study in Multiple MyelomaSeptember 13th, 2016
Sloan Kettering Taps Mobile Tools for Insight on Cancer TreatmentJuly 25th, 2016
Medidata Collaborates with Leading New York Cancer Center to Expand the Use of mHealth Technology in Oncology CareJuly 20th, 2016
Hospital Affiliations
Memorial Sloan Kettering Cancer CenterNew York, New York- Memorial Sloan Kettering BergenMontvale, New Jersey
- Memorial Hospital for Cancer and allied DiseasesBasking Ridge, New Jersey
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
